Orexo accelerates its portfolio development
Dr. Nils-Otto Ahnfelt assumes position as Project Director
Orexo uses existing and well-documented substances to rapidly develop new, innovative and patented pharmaceuticals. In 2004, the company's portfolio of development projects was further expanded and advanced. Dr. Nils-Otto Ahnfelt has been recruited as Project Director to further enhance Orexo's capacity and expertise in pharmaceutical development. He will also be a member of the Orexo Executive Management Team.
Orexo's product portfolio currently comprises a commercialized product, a number of product candidates at the clinical-development phase and some well-advanced formulation projects. The common denominator to all of Orexo's product development efforts is it's therapeutic need focus on products with considerable medical and commercial potential, which can be rapidly developed and patented at a lower risk and lower cost than conventional pharmaceutical drug discovery and development.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.